EnteroBiotix nets $25m to progress microbiome-based IBS drug
Investors have gone with their gut on EnteroBiotix’s microbiome-based lead therapy, EBX-102-02, pledging £19m ($25m) to fund a mid-stage trial…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
Veradermics’ stock grows on pivotal hair loss win
Veradermics’ share price has jumped more than 47% after its oral, extended-release version of minoxidil posted a win during a…
-
HRS 2026: Medtronic, Boston Scientific and Abbott debut key PFA data
Boston Scientific, Abbott and Medtronic all presented successful readouts of their cardiac devices during the Heart Rhythm Society’s (HRS) 2026…
-
Non-animal testing goes mainstream, but success hinges on smart use
As new approach methodologies (NAMs) burst onto the scene amid the wider shift away from animal testing, biotech and pharma…
-
Paradigm Health debuts post-marketing study tool for routine care integration
Clinical trials technology specialist Paradigm Health has introduced a new, late-phase clinical evidence generation platform, which sets out to streamline…
-
Trump backs psychedelics for mental health in new executive order
US President Donald Trump has signed an executive order focused on accelerating the route of psychedelics to the market, adding…
-
Biomarker-led trials to guide the future of precision psychiatry
As the neuroscience treatment landscape continuously evolves towards the wider use of precision treatment options, biomarker-led trials are emerging as…
-
Lilly debuts more Foundayo data as FDA requests post-marketing trials
Eli Lilly has released more data for its obesity pill, Foundayo (orforglipron) in a rapid response to US regulators voicing…
-
Storm clinches $56m in Series C for Phase II on lead sarcoma drug
British cancer biotech Storm Therapeutics has secured $56m in a Series C financing round to push its sarcoma therapy, STC-15,…
-
FDA shares guide on genome editing best practices
The US Food and Drug Administration (FDA) has debuted draft guidance for gene therapy developers, focused on the use of…